Notes d’épisode
A single FDA question, a missed clinical endpoint, or a manufacturing snag can wipe billions off a market cap in minutes, and in life sciences that kind of volatility often comes with a second hit: a securities class action. We sit down with Kevin McRoy, Executive Vice President at RT Pro Exec and author of The D&O Diary, and John Connolly, Executive Managing Director at Howden USA, leading our North American life sciences practice, to unpack why biotech, pharma, and medical device compan...

